KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Work In Process: 2018-2024

Historic Work In Process for Rigel Pharmaceuticals (RIGL) over the last 7 years, with Dec 2024 value amounting to $1.2 million.

  • Rigel Pharmaceuticals' Work In Process rose 202.98% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year increase of 202.98%. This contributed to the annual value of $1.2 million for FY2024, which is 34.65% down from last year.
  • As of FY2024, Rigel Pharmaceuticals' Work In Process stood at $1.2 million, which was down 34.65% from $1.9 million recorded in FY2023.
  • Rigel Pharmaceuticals' Work In Process' 5-year high stood at $2.7 million during FY2022, with a 5-year trough of $162,000 in FY2021.
  • Moreover, its 3-year median value for Work In Process was $1.9 million (2023), whereas its average is $1.9 million.
  • Its Work In Process has fluctuated over the past 5 years, first crashed by 86.38% in 2021, then soared by 1,541.36% in 2022.
  • Yearly analysis of 5 years shows Rigel Pharmaceuticals' Work In Process stood at $1.2 million in 2020, then plummeted by 86.38% to $162,000 in 2021, then surged by 1,541.36% to $2.7 million in 2022, then fell by 29.45% to $1.9 million in 2023, then plummeted by 34.65% to $1.2 million in 2024.